Jeffrey Jerome Ludwig - 07 Feb 2025 Form 4 Insider Report for PUMA BIOTECHNOLOGY, INC. (PBYI)

Reporting relationship: Chief Commercial Officer
Issuer ticker: PBYI
Reported as of: 07 Feb 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Feb 2025, 18:55:59 UTC
Prior SEC filing: 03 Jan 2025
Source filing: View source filing
Reporting owner signature: /s/ Gordon Esplin as attorney-in-fact for Jeffrey Jerome Ludwig

Key filing fact

Jeffrey Jerome Ludwig filed Form 4 for PUMA BIOTECHNOLOGY, INC. (PBYI) on 11 Feb 2025.

Key facts

This page summarizes Jeffrey Jerome Ludwig's Form 4 filing for PUMA BIOTECHNOLOGY, INC. (PBYI).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 11 Feb 2025, 18:55.

Change

Previous filing in this sequence was filed on 03 Jan 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PBYI transaction

Common Stock

Award

Transaction value: $0
Shares: +47,841
Change %: +44%
Price: $0.000000
Shares after: 156,792
Date: 07 Feb 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PBYI transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +66,221
Change %
Price: $0.000000
Shares after: 66,221
Date: 07 Feb 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 66,221
Exercise price: $2.78
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents Restricted Stock Units ("RSUs") that shall vest with respect to one-fourth (1/4th) of the RSUs on each of July 1, 2025, January 1, 2026, July 1, 2026 and January 1, 2027, subject to the Grantee's continued service with the Company through the applicable vesting date.

Footnote F2

Options shall vest and become exercisable with respect to one-fourth (1/4th) of the shares subject thereto on each of July 1, 2025, January 1, 2026, July 1, 2026 and January 1, 2027, subject to the Optionee's continued service with the Company through the applicable vesting date.